



GlaxoSmithKline


April 19, 2005

GlaxoSmithKline

PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709-3398

Tel. 919 483 2100
www.gsk.com

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450" under 37 CFR 1.8(a) on April 19, 2005


Patty Wilson

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Re: United States Patent No. 6,861,441
Issued: March 1, 2005
Entitled *Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer*
Serial No. 10/049,142
Filed: August 8, 2000
Attorney Docket No. PG3749USw

Sir:

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322. This request is made in order to correct the mistakes incurred through the fault of the Patent Office.

The error(s) as listed on the Certificate of Correction are references which were submitted to the U.S. Patent and Trademark Office on August 14, 2004 and considered by the Examiner on September 5, 2004. An additional copy of the Certificate of Correction is enclosed herewith, along with a return postcard in accordance with the present Patent Office practice.

Respectfully submitted,


Lorie Ann Morgan
Registration No. 38,181

LAM/ptw
Enclosures
Customer No. 23347

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,861,441

DATED : March 1, 2005

INVENTOR(S) : Nicholas Maughan Clayton, Susanne Denise Collins, Steven Michael Foord, Gerard Martin Paul Giblin, Richard John Coles, Mark Bamford, Richard Green (deceased) by Jennifer M. Doughty

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(56) References Cited

FOREIGN PATENT DOCUMENTS

WO 99 /47497
WO 00/18405
WO 00/20371
WO 00/20398

OTHER PUBLICATIONS

Dumais, N., et al., "Prostaglandin E2 Up-Regulates HIV-1 Long Terminal Repeat-Driven Gene Activity in T Cells Via NF-kB-dependent and -independent Signaling Pathways" J. Biol. Chem., vol. 273, No. 42 pp. 27306-27314.

Rufer, C., et al. "New acylated 2-(4-aminophenyl)-propionicacids as anti-inflammatory agents" Eur J. Med. Chem-chim. Ther. 13(2)(1978) pp. 193-198.

MAILING ADDRESS OF SENDER: GlaxoSmithKline

Corporate Intellectual Property
Mai B475, Five Moore Drive
P. O. Box 13398
Research Triangle Park, NC 27709-3398

PATENT NO. 6,861,441

No. of additional copies



1

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,861,441

DATED : March 1, 2005

INVENTOR(S) : Nicholas Maughan Clayton, Susanne Denise Collins, Steven Michael Foord, Gerard Martin Paul Giblin, Richard John Coles, Mark Bamford, Richard Green (deceased) by Jennifer M. Doughty

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(56) References Cited

FOREIGN PATENT DOCUMENTS

WO 99 /47497

WO 00/18405

WO 00/20371

WO 00/20398

OTHER PUBLICATIONS

Dumais, N., et al., "Prostaglandin E2 Up-Regulates HIV-1 Long Terminal Repeat-Driven Gene Activity in T Cells Via NF-kB-dependent and -independent Signaling Pathways" J. Biol. Chem., vol. 273, No. 42 pp. 27306-27314.

Rufer, C., et al. "New acylated 2-(4-aminophenyl)-propionicacids as anti-inflammatory agents" Eur J. Med. Chem-chim. Ther. 13(2)(1978) pp. 193-198.

MAILING ADDRESS OF SENDER: GlaxoSmithKline

Corporate Intellectual Property
Mai B475, Five Moore Drive
P. O. Box 13398
Research Triangle Park, NC 27709-3398

PATENT NO. 6,861,441

No. of additional copies



1